Despite prophylaxis with immunosuppressive agents or a variety of other approaches, many
patients suffer from acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic …

Management of steroid-resistant or steroid-refractory acute graft-versus-host disease
(aGVHD) poses one of the most vexing and difficult problems faced by transplantation …

Daclizumab, a humanized monoclonal IgG1 directed against the chain of the interleukin-2
receptor (IL-2R), is a competitive inhibitor of IL-2 on activated lymphocytes. To test the …

Corticosteroid resistance after acute graft-versus-host disease (SR-aGVHD) results in high
morbidity and mortality after allogeneic hematopoietic cell transplantation. Current …

A high affinity chimeric CD25 mAb (chRFT5: SDZ CHI 621) blocking interleukin-2 binding to
the interleukin-2 receptor a-chain was evaluated in a phase I/II study in human renal …

Allogeneic bone marrow transplantation (BMT) is the only curative therapy available for
patients with myelodysplastic syndrome (MDS). In an attempt to identify prognostic factors …

Humanized anti-Tac is a genetically engineered human IgG1 monoclonal antibody specific
for Tac, the alpha subunit of the interleukin-2 (IL-2) receptor, and blocks IL-2-dependent …

Acute graft-versus-host disease (GVHD) that is resistant to therapy is a highly lethal
complication of marrow transplantation. Inflammatory cytokines such as interleukin-1 (IL-1) …

Background: Daclizumab is a humanized antibody to the α-subunit (CD25) of the interleukin
2 (IL-2) receptor that blocks normal IL-2 binding to this receptor. Because IL-2 is a major …

Abstract Graft‐vs.‐host disease (GVHD) is a rare, serious complication of orthotopic liver
transplantation (OLT). We have treated 5 patients to date with GVHD after OLT. A total of 78 …